Published in Gene Therapy Weekly, November 13th, 1995
Leishmaniasis is endemic in 86 countries, including the U.S., and affects some 12 million people. The disease spectrum ranges from localized cutaneous infections to a fatal visceral disease. Other than vaccine, there is no preventive agent against this infection. Current treatments are both toxic and expensive.
The good news is that once the body elicits an immune response against the disease, reinfection is not likely. This should mean that a vaccine could be developed relatively simply, however, there is currently no safe and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.